Results 31 to 40 of about 182,825 (308)
Advances in epithelial ovarian cancer
Australian Journal of General Practice, 2020 Most epithelial ovarian cancer occurs in older women, with a mean age at diagnosis of 62 years and an overall five‑year survival rate in Australia of 43%. Most women are diagnosed with advanced disease of high-grade serous type with 20-30% five-year survival; 70% relapse within three years of initial treatment.
Deborah, Neesham +2 more
openaire +3 more sources
Targeted Therapies in Epithelial Ovarian Cancer [PDF]
Cancers, 2010 Molecularly targeted therapy is relatively new to ovarian cancer despite the unquestionable success with these agents in other solid tumours such as breast and colorectal cancer. Advanced ovarian cancer is chemosensitive and patients can survive several years on treatment. However chemotherapy diminishes in efficacy over time whilst toxicities persist.
Dean, Emma +2 more
openaire +3 more sources
Antivascular Therapy for Epithelial Ovarian Cancer [PDF]
Journal of Oncology, 2010 Ovarian cancer is the fifth largest cancer killer in women. Improved understanding of the molecular pathways implicated in the pathogenesis of ovarian cancer has led to the investigation of novel targeted therapies. Ovarian cancer is characterized by an imbalance between pro- and antiangiogenic factors in favor of angiogenesis activation.
Francois P. Duhoux, Jean-Pascal Machiels
openaire +3 more sources
Targeted anti-vascular therapies for ovarian cancer: current evidence [PDF]
, 2013 Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%.
Mcneish, I. +27 more
core +1 more source
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. [PDF]
PLoS ONE, 2009 MicroRNAs (miRNAs) are small regulatory RNAs that are implicated in cancer pathogenesis and have recently shown promise as blood-based biomarkers for cancer detection.
Stacia K Wyman +9 more
doaj +1 more source
Clinical implication for endometriosis associated with ovarian cancer
Gynecology and Minimally Invasive Therapy, 2017 We reviewed current literature regarding the association of endometriosis and epithelial ovarian cancer based on epidemiology studies, molecular researches and clinical observations. Our methods include a review of literature research of MEDLINE, PubMed,
Pao-Ling Torng
doaj +1 more source
Animal models of ovarian cancer.
, 2003 Ovarian cancer is the most lethal of all of the gynecological cancers and can arise from any cell type of the ovary, including germ cells, granulosa or stromal cells.
Jean-François Ethier +11 more
core +1 more source
Phosphatase Regenerating Liver3 and ECadherin Expression in Epithelial Ovarian Cancer
Indonesian Journal of Obstetrics and Gynecology, 2016 Objective: To determine the expression of Phosphatase Regenerating Liver-3 (PRL-3) and E-Cadherin in the epithelial ovarian cancer on various stages and differentiation grades. Method: This was a cross-sectional study design conducted at Obstetrics
Risma Maharani +2 more
doaj +1 more source
Salinomycin as a potential chemotherapeutic compound in cisplatin-resistant ovarian cancer : effects and mechanisms [PDF]
, 2013 Ovarian cancer is the most frequent cause of death from gynecological cancer. Even though there are a lot of options in treating gynecological malignancies, the therapeutic effect of ovarian cancer nowadays is still unfavourable, especially in treatment ...
Bei, Zhang
core +1 more source
Indonesian Journal of Cancer, 2014 Ovarian cancer was the leading cause of death in gynecologic cancer which had the two years recurrence rate of 50%. We used retrospective cohort design with survival analysis technique to examine the role of post-surgery residual tumor size, cancer cell ...
RESTI MULYA SARI +2 more
doaj +1 more source